Navigation Links
EGFR-targeting antibody licensed to Abbott
Date:11/17/2008

The international Ludwig Institute for Cancer Research (LICR) announced today that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate, antibody 806, to pharmaceutical company Abbott.

The 806 antibody targets the EGFR cell surface protein but crucially only when the protein is over-expressed (over-produced) in cancer. Overexpression of EGFR occurs in more than 50% of some types of cancers. Current therapies that target EGFR, such as Tarceva and Erbitux, cause side-effects by targeting EGFR both when it is overexpressed on cancer cells and when it is present in usual amounts on normal cells.

According to Prof. Andrew M. Scott, Director of the LICR Melbourne Centre, the ability of the 806 antibody to distinguish between normal EGFR and over-expressed EGFR made it the first example of a second-generation of targeting antibodies. "Our phase I clinical trial showed very clearly that the 806 antibody exquisitely targets a variety of tumours, including brain, lung, head and neck, skin and colorectal cancers. Most importantly, we demonstrated that the antibody does not bind to any normal tissues or cause any significant toxicity. This suggests the 806 antibody will have anti-tumour effects without the side effects commonly seen following treatment with other EGFR-targeting therapies."

The 806 antibody was generated in the laboratory of Dr. Lloyd J. Old, Director of the LICR New York Branch, to bind specifically to a mutant EGFR found in glioblastoma, a particular type of brain tumour. However, detailed characterization by the Institute's branches in Melbourne, New York and San Diego showed that the 806 antibody binds also to normal EGFR only when it is over-expressed, such as on cancer cells.


'/>"/>

Contact: Sarah L. White
swhite@licr.org
212-450-1543
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
2. Antibody leads to repair of myelin sheath in lab study of multiple sclerosis and related disorders
3. Antibody Helps Repair MS Nerve Damage
4. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
5. ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
6. Antibody responses in patients with Lyme arthritis
7. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
8. Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product
9. Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board
10. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
11. Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. , The study finds ...
(Date:7/29/2014)... By Dennis Thompson ... -- Exercise, a healthy diet and good sleep can protect ... down the aging process at a cellular level, researchers report. ... stressful events are linked to increased shortening of telomeres, the ... quickly cells age. "We found that over a one-year ...
(Date:7/29/2014)... 2014 During his 37 years in dental ... Associates, has had a steady stream of college students shadow ... have now gone on to dental school and some are ... shadowing program helps college students find success. , For students ... them the chance to see a realistic view of what ...
(Date:7/29/2014)... Medicine researchers have made an important advancement toward ... deadly tick-transmitted disease, human granulocytic anaplasmosis (HGA). , ... a steady rise in the incidence of human ... the need for a vaccine critical. Successful vaccine ... prevent disease, and the VCU team has identified ...
(Date:7/29/2014)... Boise, Idaho (PRWEB) July 29, 2014 ... & Hart LLP ’s Boise office, has been appointed ... Cross of Greater Idaho. , Busacker is an experienced ... executive compensation matters. He advises clients on a wide ... plan design, plan administration, compliance, and governance concerns. His ...
Breaking Medicine News(10 mins):Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2
... (cell culture) research currently underway at the Peninsula Medical School ... and develop therapies for the treatment of multiple tumours in ... a protein called merlin, which in turn cause cancers in ... brain. Schwann cells produce the sheaths that surround and insulate ...
... Makes First Investment in Antibacterial Therapeutics From ... its Biodefense and Pandemic ... today,announced the close of a $30 million Series B financing ... now completing Phase I testing. The financing was led by ...
... Group Calls for Funding Suspension After Trial ... a Baltimore Sun,opinion piece today ( http://www.baltimoresun.com/news/opinion/oped/bal ... suspension of costly HIV vaccine research funding ... proven HIV/AIDS prevention,testing and treatment strategies., ...
... take their lives in the spring, doctors say , , SUNDAY, March ... time of renewal and hope, the greatest number of suicides in ... the American College of Emergency Physicians. , It,s not clear why ... L. Lawrence. But "we do know that suicide is the 11th ...
... Music therapy can help reduce anxiety and improve physical ... everyone has used music at one time or another ... discipline of music therapy takes the use of music ... "Music therapy is an evidence-based practice that can affect ...
... YORK, March 21 Americans with ... their Medicare Advantage Plan have an ... to this report from UnitedHealthcare at:, ... access video, audio, text, graphics and,photos ...
Cached Medicine News:Health News:Research to lead to brain tumor therapies 2Health News:Research to lead to brain tumor therapies 3Health News:Trius Raises $30 Million in Series B Financing 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 3Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 4Health News:Know Suicide's Warning Signs 2Health News:Know Suicide's Warning Signs 3Health News:Music as Medicine 2Health News:Music as Medicine 3
(Date:7/29/2014)... 29, 2014  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... on Thursday, August 7, 2014 at 11:00 AM Eastern ... ended June 30, 2014 and to provide a business ... second quarter conference call may be accessed by dialing ...
(Date:7/29/2014)... 2014 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today reported net income for the quarter ... diluted share, and non-GAAP net income of $94.0 million, or ... a year earlier was $93.3 million, or $0.81 per diluted ... per diluted share.  Net sales for the ...
(Date:7/29/2014)... -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of ... that cause serious infections and diseases, announced today that ... Company,s stock, the NYSE MKT (the "Exchange") has contacted ... Company stated that its policy is not to comment ... Inc. Synthetic Biologics, Inc. (NYSE MKT: SYN) ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... Report from Trial of Quadramet in Combination with Velcade for ... 11 Quadramet (153 Samarium-lexidronam) is ... and is used to treat pain caused by cancer that ... (bortezomib) is approved for the treatment of ...
... 10 Endo Pharmaceuticals (Nasdaq: ENDP ) ... agreements to develop novel treatments for pain and to ... with Harvard University , is based upon a ... Harvard Medical School,s Richard J. Kitz Professor of Anaesthesia ...
Cached Medicine Technology:Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results 2Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 2Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 3
Bi-phasic peristaltic infusion pump for tumescent work....
... a compact system featuring,easy setup and flow ... allowing the use of less,expensive disposable tubing ... office or hospital use, the,PSI-TEC III Infiltrator ... - 5" (w) X 8" (l) X ...
... represents a major advance in the ... procedures. Combined with precision fluid management, ... solid grooved probe design and patented ... been designed to minimize trauma to ...
Inquire...
Medicine Products: